NEDD4L and ovarian cancer: In solid tumors, such as non-small-cell lung cancer (NSCLC) (Sakashita et al., 2013; Li G. et al., 2022), ovarian cancer (Yang et al., 2015), hepatocellular carcinoma (Zhao et al., 2018), renal clear cell carcinoma (Zhao et al., 2021), malignant glioma of the brain (He et al., 2012) and gastric cancer (Gao et al., 2012; Jiang et al., 2019), patients in the low-NEDD4L-expression group have worse prognoses and shorter survival than those in the high-expression group.